FDA hands Paradigm Biopharma guidance to re-jig phase 3 osteo trial – or is it a delay?
Paradigm Biopharmaceuticals (ASX:PAR) has confirmed that it will use a twice weekly…
Paradigm Biopharmaceuticals Limited.. (ASX:PAR)
About Paradigm Biopharmaceuticals Limited..
Key Information
PAR In the News
ASX Announcements
| Date | Announcement | File | Views |
|---|---|---|---|
| 31/10/2024 | Price Sensitive PS Quarterly Activities/Appendix 4C Cash Flow Report | 322.75KB | 12K |
| 31/10/2024 | Price Sensitive PS Phase 3 Protocol Submission to US FDA | 154.85KB | 17K |
| 24/10/2024 | Proposed issue of securities - PAR | 16.89KB | 704 |
| 23/10/2024 | Change of Director's Interest Notice | 169.23KB | 625 |
| 23/10/2024 | Change of Director's Interest Notice | 178.58KB | 609 |
| 22/10/2024 | Notification of cessation of securities - PAR | 13.38KB | 607 |
| 21/10/2024 | Price Sensitive PS Paradigm Investor Update | 150.6KB | 76K |
| 18/10/2024 | Notice of Annual General Meeting/Proxy Form | 623.74KB | 45K |